Butyrylcholinesterase as a marker of low-grade systemic inflammation

摘要

The present invention relates to a strategy or method of detecting, diagnosing, and prognosticating low-grade systemic inflammatory conditions such as insulin resistance, type 2 diabetes mellitus, hypertension, hyperlipidemias, and Alzheimer's disease; various cancers, and acute and chronic collagen vascular diseases including rheumatoid arthritis (RA), and lupus; proliferative diabetic retinopathy; macular degeneration; multiple sclerosis, psoriasis, chronic renal failure, end-stage renal disease, glomerulonephritis including minimal change nephropathy, proliferative glomerulonephritis, nephritis secondary to underlying systemic diseases using plasma and/or tissue levels of acetylcholinesterase and butyrylcholinesterase as a marker. The method employed to detect acetylcholinesterase and butyrylcholinesterase could include various methods such as but not limited to turbimetric test, or ELISA (enzyme linked immunosorbent assay), fluorometric, radioimmunoassay, and spectrophotometric methods.